Company intelligence / Profile preview

inTUMO Therapeutics

California, United Statesrocketreach.co ↗

Ownership: Private
Development stage: Preclinical

Overview

Currently conducting a clinical trial to evaluate if INT001 can ablate liver tumors in adults in an outpatient setting and assess its safety. The trial involves 31 participants who receive INT001 on day 1 and follow-up visits on days 7, 30, and 90, with MRI evaluations on days 30 and 90[2].

Therapeutic areas: Oncology
Modalities: Locoregional treatment technology
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on inTUMO Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inTUMO Therapeutics.

Explore the full profile